Preclinical evidence demonstrates sensitivity of PIK3CA mutatedbreast cancer cells to PI3K blocking agents [69,70] and, with p110α isoform-selective inhibitors being under clinicaldevelopment, there is the promise for more potent target inhibition coupled with amilder toxicity profile [71]. This evidence concerns the gene PIK3CD and cancer.